Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Roasted Nux Vomica for Bortezomib-Related Peripheral Neuropathy
NCT07614243Completed
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Aug 2020
- Primary completion
- Aug 2022
- Countries
- 1
01
Overview
Open-label, single-arm trial in chemotherapy-induced peripheral neuropathy (CIPN), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: National Cancer Institute Common Terminology Criteria for Adverse Events Grade at 6 weeks. Started Aug 2020; status: completed.
02
Conditions
chemotherapy-induced peripheral neuropathy (CIPN)
Beyond the preview
Go deeper on NCT07614243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07614243.